[1] Pfutze M, Niedermeier A, Hertl M, et al.Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus[J]. Eur J Dermatol, 2007, 17(1): 4-11. [2] 杜文辉,李卉,王培光,等. 天疱疮与大疱性类天疱疮患者3种实验检测结果比较[J]. 安徽医学,2017,38(9):1164-1166. [3] 赵辨. 中国临床皮肤病学[M]. 南京:江苏科学技术出版社,2012,833-839. [4] Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al.Pemphigus[J]. Nature Reviews Disease Primer, 2017, 3(1): 461-474. [5] Khandpur S, Sharma VK, Sharma A, et al.Comparison of enzyme-linked immunosorbent assay test with immunoblot assay in the diagnosis of pemphigusin Indian patients[J]. Indian J Dermatol Venereol Leprol, 2010, 76(1): 27-32. [6] 柯丹,杜宇,邓抒琴,等. 天疱疮患者抗桥粒芯糖蛋白与疾病相关性分析[J]. 重庆医学,2016,45(18):2498-2499. [7] 李锁,李志量,荆可,等. 桥粒芯糖蛋白抗体与天疱疮临床表型和疾病活动度的关系及其变化规律[J]. 中华皮肤科杂志,2019(5):297-301. [8] Russo I, De Siena FP, Saponeri A, et al.Evaluation of anti-desmoglein-1 and anti-desmoglein-3 autoantibody titers in pemphigus patients at the time of the initial diagnosis and after clinical remission[J]. Medicine, 2017, 96(46): e8801. [9] 纪燕云,陈永锋,张庆英,等. 天疱疮患者治疗中桥粒芯蛋白抗体的变化及临床意义[J]. 汕头大学医学院学报,2016,29(3):159-160,163. [10] 周小芳,宋志强,邓向芬,等. 血清抗桥粒芯蛋白1和3抗体在天疱疮临床诊断中的意义[J]. 实用皮肤病学杂志,2019,12(2):82-83,86. [11] Patsatsi A,Kyriakou A,Giannakou A,et al.Clinical significance of anti-desmoglein-1 and -3 circulating autoantibodies in pemphigus patients measured by area index and intensity score[J]. Acta Derm Venereol, 2014, 94(2): 203-206. [12] Barnadas MA, Rubiales MV, Gich I, et al.Usefulness of specific anti-desmoglein 1 and 3 enzyme-linked immunoassay and indirect immunofluorescence in the evaluation of pemphigus activity[J]. Int J Dermatol, 2015, 54(11): 1261-1268. [13] 朱海琴,潘萌,陈娅苑,等. 天疱疮特异性抗体亚型与疾病活动的相关性研究[J]. 中华皮肤科杂志,2011,44(1):7-10. [14] Kwon EJ, Yamagami J, Nishikawa T, et al.Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission[J]. Journal of the European Academy of Dermatology and Venereology, 2008, 22(9): 1070-1075. [15] 周志军,胡珊,高庆,等. Dsg1、Dsg3抗体检测在天疱疮疾病诊断和治疗中的应用[J]. 实验与检验医学,2017,35(1):41-42,46. |